Mary Wilson
Well-known member
JAMA. Published online August 18, 2021.
doi:10.1001/jama.2021.14811
Carlos del Rio, MD[SUP]1,2[/SUP]; Preeti N. Malani, MD, MSJ[SUP]3,4[/SUP]; Saad B. Omer, MBBS, PhD[SUP]5,6[/SUP]
A vailability of safe and highly effective SARS-CoV-2 vaccines increased the possibility of durable control of COVID-19 both in the US and worldwide. After initial challenges in vaccine supply and delivery, there was substantial progress in vaccinating US residents. The arrival of spring 2021 and increasing vaccination rates, particularly among individuals at high risk for severe infection and complications, was followed by a steady decline in cases, hospitalizations, and deaths.
As of August 16, 2021, the US Centers for Disease Control and Prevention (CDC) estimates that 168.7 million people have been fully vaccinated in the US, which represents 50.8% of the population and 59.4% of the vaccine-eligible population.[SUP]1[/SUP] However, there are large variations in vaccination rates by state, with a high of 76.9% in Vermont to a low of 44% in Alabama. Moreover, immunization rates have plateaued, largely due to a lack of focus on the various behavioral aspects of vaccine uptake, especially a new vaccine that would need to be given to virtually every eligible person in the US.
... Based on these and other data, on August 13, 2021, the US Food and Drug Administration (FDA) modified the current Emergency Use Authorization and the CDC now recommends administering a third dose of an mRNA vaccine to immunocompromised individuals 28 days after the second dose.[SUP]7[/SUP] Even though an estimated 10 million people in the US may be considered immunocompromised, this recommendation applies to only a small subset of them, including the following:
https://jamanetwork.com/journals/ja...m=social&utm_term=081821#.YR0zfYOWgPc.twitter
doi:10.1001/jama.2021.14811
Carlos del Rio, MD[SUP]1,2[/SUP]; Preeti N. Malani, MD, MSJ[SUP]3,4[/SUP]; Saad B. Omer, MBBS, PhD[SUP]5,6[/SUP]
A vailability of safe and highly effective SARS-CoV-2 vaccines increased the possibility of durable control of COVID-19 both in the US and worldwide. After initial challenges in vaccine supply and delivery, there was substantial progress in vaccinating US residents. The arrival of spring 2021 and increasing vaccination rates, particularly among individuals at high risk for severe infection and complications, was followed by a steady decline in cases, hospitalizations, and deaths.
As of August 16, 2021, the US Centers for Disease Control and Prevention (CDC) estimates that 168.7 million people have been fully vaccinated in the US, which represents 50.8% of the population and 59.4% of the vaccine-eligible population.[SUP]1[/SUP] However, there are large variations in vaccination rates by state, with a high of 76.9% in Vermont to a low of 44% in Alabama. Moreover, immunization rates have plateaued, largely due to a lack of focus on the various behavioral aspects of vaccine uptake, especially a new vaccine that would need to be given to virtually every eligible person in the US.
... Based on these and other data, on August 13, 2021, the US Food and Drug Administration (FDA) modified the current Emergency Use Authorization and the CDC now recommends administering a third dose of an mRNA vaccine to immunocompromised individuals 28 days after the second dose.[SUP]7[/SUP] Even though an estimated 10 million people in the US may be considered immunocompromised, this recommendation applies to only a small subset of them, including the following:
- Active treatment for solid tumor and hematologic malignancies
- Receipt of solid organ transplant and taking immunosuppressive therapy
- Receipt of CAR T-cell or hematopoietic stem cell transplant (within 2 years of transplant or taking immunosuppressive therapy)
- Moderate or severe primary immunodeficiency (eg, DiGeorge syndrome, Wiskott-Aldrich syndrome)
- Advanced or untreated HIV infection
- Active treatment with high-dose corticosteroids, alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, TNF blockers, and other biologic agents that are immunosuppressive or immunomodulatory
https://jamanetwork.com/journals/ja...m=social&utm_term=081821#.YR0zfYOWgPc.twitter